At a glance
| Product | Maker | Material and how it works | MFDS and FDA status | Downtime and risks, as stated by the sources |
|---|---|---|---|---|
| Rejuran (Healer, HB plus, i, S) | PharmaResearch (Gyeonggi-do, South Korea); launched in 2014 | Polynucleotide (PN) from salmon DNA, injected into ageing or damaged skin, where it acts as a physical scaffold. PN is made of longer DNA fragments and is thought to work mainly by remodeling the skin's extracellular matrix | MFDS: PN injectables are regulated as medical devices; HB plus approved in July 2021; Rejuran i and S approved on 31 Aug 2016; the original Healer's approval date and number not confirmed. FDA: no approval or clearance found in our sources | Most reported reactions are local swelling, discomfort and slight bruising, and injections leave small raised bumps. A 2024 systematic review of PN studies found no severe adverse events in the included studies |
| Juvelook (Skin, Volume) | VAIM Inc. (Seoul, South Korea) | PDLLA microparticles with non-cross-linked hyaluronic acid, supplied as a powder that the clinic mixes with sterile water. Injected into the dermis to induce the body's own collagen | MFDS: classified as a medical device, approved by MFDS and CE-marked; approval date and number not confirmed, and no separate record found for Juvelook Volume (also sold as Lenisna). FDA: no approval or clearance found in our sources | In a lower-eyelid case series, mild bruising and swelling settled within 48 hours. The main concern with PDLLA injections is granulomas, which are firm, red nodules at the injection site |
A "clearance" is not an approval. Where the table gives the maker's own statement, it is not independent evidence.
How they differ
Material and mechanism
- Rejuran. PN consists of longer DNA fragments than the related PDRN. It forms a porous, highly viscous three-dimensional structure, which is why it behaves as a hydrating scaffold. It is thought to work mainly by remodeling the extracellular matrix. Rejuran Healer launched in Korea in 2014.
- Juvelook. PDLLA is a biodegradable polymer that stimulates collagen synthesis. It is also reported to shift immune cells (macrophages) toward the anti-inflammatory M2 type. Juvelook combines PDLLA with non-cross-linked hyaluronic acid, and most Korean PDLLA studies used it.
Product lines
- Rejuran has several versions. Rejuran HB plus adds hyaluronic acid and a local anesthetic to PN. The maker says the anesthetic cut procedure pain by 53% versus Rejuran Classic, but that is a company figure reported by the press, not an independent study. Rejuran i (also sold by clinics as Rejuran Eye) has a lower viscosity and spreads more, so it suits thin skin such as around the eyes.
- Juvelook has two lines by purpose. Juvelook Skin is for fine lines and texture. Juvelook Volume, also sold as Lenisna, is for hollows and the lines from the nose to the mouth. Each Volume vial contains 170 mg of PDLLA and 30 mg of non-cross-linked hyaluronic acid.
Sessions and how long they last
- Rejuran. Expert guidance from the authors' clinical experience is 3 sessions at 4-week intervals for skin hydration and rejuvenation. For laxity the same experts suggest 3 sessions at 4-week intervals, then maintenance every 3 months. A randomized split-face trial of Rejuran for the eye area gave 3 treatments at 2-week intervals. We found no maker-stated duration.
- Juvelook. Studies in a 2024 review gave PDLLA injections at 3-month intervals. A tear-trough case series used a single session. VAIM says the effects last about 12 months for Juvelook and 1.5 to 2 years for Juvelook Volume. That is a company claim.
Risks to know about
- For PN, a systematic review found no severe adverse events in the included studies, and reactions were mostly local swelling, discomfort and slight bruising.
- For PDLLA, the main concern is granulomas. A review also notes that even small poly-lactic acid particles can block blood vessels and cause tissue ischemia if injected into a vessel.
- Your doctor explains the risks for your skin before treatment.
Regulatory claims to check
In Korea, PN products such as Rejuran are regulated as medical devices, and Juvelook is a medical device approved by MFDS. We found no FDA record for either. Some clinic pages abroad call Juvelook "FDA-approved", and we found no FDA record to support that. A PDLLA polymer being accepted by the FDA as a material is not the same as the Juvelook product being approved. Ask a clinic for the product's MFDS approval, not just a statement about the FDA.
Published prices in this directory
The table shows the lowest and highest published regular price per treatment. Amounts and units differ: Rejuran is usually listed per session by the cc, and Juvelook per cc or per vial. Check the item and the amount before you compare.
| Item | Clinics in this directory | Published regular prices (lowest) | Published regular prices (highest) |
|---|---|---|---|
| Rejuran 리쥬란 | 19 | ₩40,000 (≈ US$30) JRYN Skin Clinic Seomyeon · Rejuran Skin Booster 1 cc · VAT excluded | ₩1,400,000 (≈ US$1,060) Will Be Plastic Surgery · Rejuran 4cc (full face) · VAT not stated |
| Juvelook 쥬베룩 | 16 | ₩20,000 (≈ US$15) Beauty Park Skin Clinic Beomeo · Juvelook for a single scar · 0.2 cc · VAT excluded | ₩2,100,000 (≈ US$1,590) EU:GENES Skin Clinic · Juvelook Volume, 3 areas, 3 sessions · VAT excluded |
Facts come from the sources listed on this page; prices from the clinics' own price lists, checked up to 29 October 2026. Prices differ in product, amount and VAT basis.
Which one to ask about
This page does not rank the products. The doctor decides after an examination. Questions to ask the clinic:
- Which exact product is it: Rejuran Healer, HB plus or i, or Juvelook Skin or Volume? Ask to see the box and the label.
- How many cc or vials does the price include?
- Which area is it for, and what is the aim: skin quality, the eye area or hollows?
- How many sessions and what interval does the doctor suggest, and what happens if I need a touch-up?
- What does the price include, for example numbing or cooling?
- Can the clinic show the product's MFDS approval?
- Who injects, and does the price change if the head doctor does it?
- Is VAT included (부가세 별도 means VAT is charged on top), and is this a regular or an event price?
Read more on the Rejuran, Juvelook and skin booster pages.
FAQ
What is the difference between Rejuran and Juvelook?
Rejuran is polynucleotide made from salmon DNA, which acts as a physical scaffold in the skin. Juvelook is PDLLA microparticles with hyaluronic acid, which stimulate the skin to make its own collagen. Rejuran is made by PharmaResearch and Juvelook by VAIM, both in Korea. Both are regulated as medical devices in Korea.
Is Rejuran or Juvelook FDA approved?
We found no FDA approval or clearance for Rejuran or Juvelook in our sources. Some clinic pages call Juvelook FDA-approved, and no FDA record supports that. In Korea, PN products such as Rejuran are regulated as medical devices, and Juvelook is an MFDS-approved device. Ask the clinic for the MFDS approval of the exact product.
Which is better, Rejuran or Juvelook?
We do not rank them. They are different materials with different mechanisms and different uses: Rejuran for skin quality, including a thin-skin version for the eyes, and Juvelook Skin or Volume for fine lines or hollows. We found no head-to-head study. Your doctor chooses after examining your skin and your goals.
How many Rejuran or Juvelook sessions do I need?
Expert guidance for PN products such as Rejuran is 3 sessions at 4-week intervals, with maintenance every 3 months for laxity. Studies of PDLLA products such as Juvelook gave injections at 3-month intervals. Your doctor decides the number and the interval. Ask whether a price covers one session or a package.
What are the side effects of Rejuran and Juvelook?
For PN, the most reported reactions are local swelling, discomfort and slight bruising, and a systematic review found no severe adverse events. For PDLLA, the main concern is granulomas, firm red nodules at the injection site. Bruising and swelling in one eyelid series settled within 48 hours. Your doctor explains the risks.
Sources
- 데일리팜 (Dailypharm): 파마리서치 '리쥬란' 심포지엄 의료진 관심, 2017-04-10
- Journal of Cosmetic Dermatology / PMC: The Effectiveness of Polynucleotides in Esthetic Medicine: A Systematic Review (J Cosmet Dermatol, 2024)
- Pharmaceutics (MDPI) / PMC: Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (Pharmaceutics, 2025)
- 데일리팜 (Dailypharm): 파마리서치, 리쥬란 업그레이드 버전 국내 허가, 2021-07-30
- 데일리팜 (Dailypharm): 통증 적은 파마리서치 '리쥬란HB plus' 입소문, 2024-04-09
- 데일리팜 (Dailypharm): 파마리서치, 피부미용주사 신제품 출시 (리쥬란 아이·리쥬란 에스 본격 발매), 2016-09-20
- Journal of Cosmetic Dermatology / PMC: A Novel Classification System of Skinboosters to Support Clinical Decision Making (J Cosmet Dermatol, 2026)
- Archives of Plastic Surgery / PMC: Injectable “Skin Boosters” in Aging Skin Rejuvenation: A Current Overview (Arch Plast Surg, 2024)
- Clinical, Cosmetic and Investigational Dermatology / PMC: Expert Perspectives: Evidence-Based Applications of Polynucleotides (PNs) in Aesthetic Medicine and Dermatology (CCID, 2026)
- 메디칼타임즈 (Medical Times): 효과‧안전성 입증한 쥬베룩, 스킨부스터 시장 다크호스, 2022-12-13
- Polymers (MDPI) / PMC: Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review (Polymers, 2024)
- Journal of Cosmetic Dermatology / PMC: Facial Ligament Thickening Using Poly-D,L-Lactic Acid Injection (J Cosmet Dermatol, 2025)
- 딜사이트 (Dealsite): 스킨부스터 열전 바임 '쥬베룩', 리쥬란과 유럽서 각축전, 2025-10-22
- Journal of Cosmetic Dermatology / PMC: Evaluating Poly-D,L-Lactic Acid for Lower Eyelid Rejuvenation: Efficacy and Safety (J Cosmet Dermatol, 2025)
Prices in the tables are the regular prices that clinics in this directory publish on their own price lists, checked at each update.